SCHEMBL3705973

SCHEMBL3705973

Nc1cc2oc3ccccc3c2cc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.56
MEN1 O00255 3/20 0.56
MAPT P10636 3/20 0.56
HPGD P15428 3/20 0.56
KMT2A Q03164 3/20 0.56
ALDH1A1 P00352 2/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
AHR P35869 2/20 0.52
TBK1 Q9UHD2 1/20 0.49
NQO1 P15559 1/20 0.47
MAOA P21397 4/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA9 Q16790 1/20 0.46
GAA P10253 2/20 0.44
CYP3A4 P08684 1/20 0.44
ALPI P09923 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3878268 0.93 KDM4E (0.56) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL3876540 0.86 EGFR (0.42) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL3886475 0.84 MAPT (0.64) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL3874960 0.84 AHR (0.59) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL26450313 0.79 AHR (0.58) KDM4EHPGDALDH1A1SMN1; SMN2AHR
SCHEMBL26450328 0.79 AHR (0.53) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL172890 0.78 MAOA (0.54) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL15840239 0.78 AHR (0.72) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL31192626 0.78 AHR (0.52) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL25531245 0.78 HPGD (0.56) KDM4EMEN1MAPTHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080098535-A1 Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof GLENN ROBERT W JR 2008-05-01 US claimed
US-20050217038-A1 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof PROCTER & GAMBLE COMPANY, THE 2005-10-06 US claimed
US-11877512-B2 Organic electroluminescence device and compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2024-01-16 US disclosed
US-11877512-B2 Organic electroluminescence device and compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2024-01-16 US disclosed
CN-115043852-B Benzoxazole derivative and electroluminescent application thereof 武汉天马微电子有限公司 2023-12-29 CN disclosed
US-20230139051-A1 BENZOXAZOLE DERIVATIVE AND ELECTROLUMINESCENT APPLICATION THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-05-04 US disclosed
US-20230139051-A1 BENZOXAZOLE DERIVATIVE AND ELECTROLUMINESCENT APPLICATION THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-05-04 US disclosed
US-20230139051-A1 BENZOXAZOLE DERIVATIVE AND ELECTROLUMINESCENT APPLICATION THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-05-04 US disclosed
CN-115043852-A Benzoxazole derivative and electroluminescent application thereof 武汉天马微电子有限公司 2022-09-13 CN disclosed
US-20210098708-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2021-04-01 US disclosed
EP-3356355-B1 COMPOUNDS AND COMBINATIONS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2020-05-13 EP disclosed
US-20060229303-A1 Substituted quinobenzoxazine analogs CYLENE PHARMACEUTICALS, INC. 2006-10-12 US disclosed
WO-2006078317-A1 SUBSTITUTED QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF CYLENE PHARMACEUTICALS, INC. (US) 2006-07-27 WO disclosed
CN-1809572-A Substituted quinobenzoxazine analogs CYLENE PHARMACEUTICALS INC (US) 2006-07-26 CN disclosed
US-20060029950-A1 Substituted quinobenzoxazine analogs and methods of using thereof CYLENE PHARMACEUTICALS, INC. 2006-02-09 US disclosed
EP-1610759-A2 SUBSTITUTED QUINOBENZOXAZINE ANALOGS Cylene Pharmaceuticals, Inc. (US) 2006-01-04 EP disclosed
WO-2005099656-A2 KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF THE PROCTER & GAMBLE COMPANY (US) 2005-10-27 WO disclosed
US-20050217038-A1 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof PROCTER & GAMBLE COMPANY, THE 2005-10-06 US disclosed
US-20050085468-A1 Substituted quinobenzoxazine analogs CYLENE PHARMACEUTICALS 2005-04-21 US disclosed
WO-2004091504-A2 SUBSTITUTED QUINOBENZOXAZINE ANALOGS CYLENE PHARMACEUTICALS, INC. (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050217038-A1 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof KRT18, CKMT1A; CKMT1B, TUBB6 KDM4E 1549/4885MEN1 4857/4885MAPT 420/4885
US-20050085468-A1 Substituted quinobenzoxazine analogs CYP3A5, UGT2B7, CYP2D6 KDM4E 1205/4885MEN1 3714/4885MAPT 3632/4885
US-20230139051-A1 BENZOXAZOLE DERIVATIVE AND ELECTROLUMINESCENT APPLICATION THEREOF TSPO, XDH, TARS2 KDM4E 1209/4885MEN1 4735/4885MAPT 1395/4885
US-11877512-B2 Organic electroluminescence device and compound for organic electroluminescence device LEF1, PIEZO1, L1CAM KDM4E 1030/4885MEN1 1432/4885MAPT 2625/4885
US-20060229303-A1 Substituted quinobenzoxazine analogs CYP3A5, UGT2B7, CYP2D6 KDM4E 1205/4885MEN1 3714/4885MAPT 3632/4885
US-20080098535-A1 Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof KRT18, CKMT1A; CKMT1B, TUBB6 KDM4E 1549/4885MEN1 4857/4885MAPT 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.